Trisha Coover
Family · Tomball, TXNPI 1407115009
Payments from drug & device makers
Across 253 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$787
- AstraZeneca$640
- Amgen$501
- Indivior Inc.$384
- Lilly USA, LLC$233
- Amarin Pharma, Inc.$229
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,650100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $787 |
| AstraZeneca | 25 | $640 |
| Amgen | 37 | $501 |
| Indivior Inc. | 9 | $384 |
| Lilly USA, LLC | 14 | $233 |
| Amarin Pharma, Inc. | 12 | $229 |
| Novo Nordisk | 12 | $229 |
| Pfizer | 9 | $172 |
| GSK | 9 | $151 |
| Inspire Medical Systems, Inc. | 5 | $117 |
| Exact Sciences | 6 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $92 |
| Johnson & Johnson | 4 | $92 |
| Bayer | 5 | $84 |
| Baxter Healthcare | 2 | $63 |
| Orexo US, Inc. | 2 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $49 |
| Medtronic | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Shield Therapeutics Inc | 3 | $44 |
| Corium, LLC | 2 | $40 |
| Organon | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $37 |
| Viatris Specialty LLC | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Braeburn Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Echosens North America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,664 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $58,003 |
| XareltoRivaroxaban | 21 | $26,975 |
| TrulicityDulaglutide | 15 | $23,795 |
| EliquisApixaban | 26 | $23,755 |
| OzempicSemaglutide | 15 | $21,943 |
| VascepaIcosapent Ethyl | 27 | $14,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,849 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 65 | $13,477 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $11,954 |
| Nurtec OdtRimegepant Sulfate | 11 | $11,679 |
| LinzessLinaclotide | 23 | $11,408 |
| Repatha SureclickEvolocumab | 13 | $11,158 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $6,831 |
| MyrbetriqMirabegron | 12 | $5,472 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $640 | $58,00352 claims |
| PfizerEliquis, Nurtec Odt | $172 | $35,43437 claims |
| Johnson & JohnsonXarelto | $92 | $26,97521 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $151 | $25,80343 claims |
| Lilly USA, LLCTrulicity | $233 | $23,79515 claims |
| Novo NordiskOzempic | $229 | $21,94315 claims |
| AbbVieLinzess, Synthroid | $787 | $12,65639 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $5,47212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Tomball
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.